SCHEMBL3011980

SCHEMBL3011980

CCOc1ccc(-c2csc(N3CCN(S(=O)(=O)c4ccccc4C#N)CC3)n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.55
MAPK1 P28482 4/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
SMN1; SMN2 Q16637 6/20 0.53
MAPT P10636 6/20 0.53
ALDH1A1 P00352 5/20 0.53
L3MBTL1 Q9Y468 1/20 0.48
HTT P42858 2/20 0.47
KDM4E B2RXH2 1/20 0.46
PKM P14618 1/20 0.46
GBA1 P04062 2/20 0.45
POLB P06746 1/20 0.44
USP2 O75604 1/20 0.44
RECQL P46063 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TSHR P16473 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014968 0.90 ALDH1A1 (0.55) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3013599 0.88 LMNA (0.58) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3008044 0.87 LMNA (0.59) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3009105 0.87 ALDH1A1 (0.58) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3004662 0.87 LMNA (0.63) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3011627 0.86 LMNA (0.56) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3009126 0.86 LMNA (0.58) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3013763 0.86 MAPT (0.46) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3007583 0.86 HTT (0.45) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3011400 0.85 MAPT (0.58) LMNAMAPK1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MAPK1 2767/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.